Certara | GenomeWeb

Certara

NantHealth said this week that it has launched a fully integrated genomic and transcriptomic analytic engine that can identify mutations such as copy number variants and genomic rearrangements in DNA, RNA, and protein pathways accurately and efficiently.

Certara has hired Edmundo Muniz as its CEO.

This week, Thomson Reuters launched Cortellis Data Fusion, an addition to the company's Cortellis suite, which provides access to information for drug discovery and development.

Certara said this week that Medivir, a Swedish pharmaceutical company that focuses on infectious diseases such as hepatitis C, has selected its D360 software as its global drug discovery platform.

Arsenal Capital Partners, a New York-based private equity firm, has bought Certara, a provider of model-based drug development and data analytics software and consulting services, from Vector Capital for an undisclosed sum.

NEW YORK (GenomeWeb News) – Private equity firm Arsenal Capital Partners today announced it has bought Certara, a provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.

Certara and LabLogic Systems have signed an agreement to integrate software products in their portfolios.

Certara said this week that it is partnering with Thomson Reuters to provide customers of its D360 software solution with access to content contained in Thomson Reuters' Cortellis for Informatics system.

NEW YORK (GenomeWeb News) – Certara said this week that it is working with the Critical Path Institute, C-Path, to create a physiologically-based pharmacokinetic model of the human lung using Certara's Simcyp Population-based simulator software that will be used to test new tuberculosis drugs.

Certara has released version 13 of the Simcyp Simulator, its software for quantitative prediction of drug-drug-interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.